Systemic anaplastic large cell lymphoma: Management of first relapse or primary refractory disease

This algorithm describes management of relapsed or refractory sALCL. Refer to related UpToDate material for details of diagnosis, treatments, and response-guided therapy.

sALCL: systemic anaplastic large cell lymphoma; BV: brentuximab vedotin; ALK: anaplastic lymphoma kinase; PET3: positron emission tomography performed after three cycles of induction therapy.

* We favor response-guided therapy using PET3 to determine preliminary tumor responsiveness; duration of therapy is guided by whether transplantation is planned.

Graphic 142679 Version 1.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟